

MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement sets forth the terms and conditions (see also Apendices) under which Mitani Laboratory at the Tokyo Women's Medical University School of Medicine (hereinafter referred to as 'Mitani lab') will provide with the recipient, and the recipient will receive, the biological material specified as:

(allele names here)

and/or its unmodified derivatives (hereinafter referred to as the 'biological resource') with which the recipient staff and organization agree before the recipient receives the biological resource:

1. The Mitani lab is engaged in developing, collecting, maintaining, storing, multiplying and distributing the biological resources to contribute to the research community in the field of life sciences.
2. The recipient shall use the biological resource only for the following specific purpose:

3. The recipient shall not use the biological resource for diagnosis or treatment of humans or other direct applications to human bodies or as food source for humans.
4. The recipient agrees to expressly describe the acknowledgement of the Mitani lab as the source of the biological resource in any publication reporting the use thereof and the recipient shall send a copy of reprint or an equivalent of publication to the Mitani lab. The Mitani lab may disclose publicly such publication by citing "corresponding author, Journal name, volume, pages and publication year".
5. The recipient shall not distribute, resell or otherwise dispose of the biological resource and its unmodified derivatives to any third party without permission by the Mitani lab.
6. Nothing in this agreement shall be interpreted that the Mitani lab grants the recipient any rights under any patents or other intellectual property or licenses thereunder with respect to the biological resource.
7. The recipient acknowledges that the biological resource delivered pursuant to this agreement may have defective, hazardous or faulty properties and may not necessarily fit for a particular purpose and that the recipient assumes all liability for any consequences resulting from the use by the recipient of the biological resource.
8. The recipient agrees that any handling or other activities undertaken in their laboratory with the biological resource shall be conducted in compliance with all applicable laws, regulations and guidelines.

The recipient and the Mitani lab do hereby sign two original copies of this agreement and each party holds one signed copy.

Mitani lab (depositor & distributor)

Organization and Address: Department of Physiology, Tokyo Women's Medical University
School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

Authorized Representative: Shohei Mitani, M.D., Ph.D.

Title: Professor and Chair

Signature: _____

Date: _____

Recipient (Principal Investigator)

Name: _____, Title: _____

Affiliation and Address (where biological materials are sent to):

e-mail address of Principal Investigator: _____

Signature: _____

Date: _____

Recipient (Technical License Office or Institutional Representative, if applicable)

Name and Address of Authorized Representative: _____

e-mail address of the Representative: _____

Title: _____

Signature: _____

Date: _____

APPENDIX 1: Instructions for recipients

1. Please fill in the form clearly. Especially **name and address are important** to receive biological materials. Principal investigator's address should be the place where researchers are working but not technical license offices are located. **If researcher's address and affiliation have been changed after he/she received strains the last time, please stress the change so that we should not send biological resources to the old address.**
2. Biological resources should be **indicated by allele names**, for example, "tm2222". More than one biological resources can be included in a form, for example, "tm1111 and tm2222".
3. If the MTA is necessary to be sent separately to technology license office directly instead of forwarding via researcher's laboratory, please **enclose a mailing envelope** with the addressee (otherwise we will send MTA via researchers).
4. **Always Principal Investigator (PI) should sign** in the form to show clearly the laboratory designation. Technical assistants, students, postdoctoral researchers, research associates should not sign as a PI. "Authorized Representative" can be left empty if "Principal Investigator" is the same as "Authorized Representative".
5. "**Title**" of the Principal Investigator should be the "institutional title", for example, like "**Professor**", "**Team leader**" and so on, but should not be like "Ph.D" or "scientist".
6. The form **should not be sent by FAX**, because print-outs are often unclear. To send forms more quickly, clearly scanned (for example 300 dpi) and saved as a PDF file can be sent by an attachment of e-mail.
7. "Purpose" of the biological resources can be written simply, for example, "**phenotype analysis**" or "**as a parent strain to screen for suppressor**" etc. Recipients don't need to describe the details of the research plan.
8. Please confirm that recipients did feedback to the core facility before you send the form. Now the "National Bioresource Project for the nematode" requires recipients to feedback your observation and there is a limit of 10 alleles for one laboratory to receive without feedback. **Recipients may not be able to receive biological resources even if the MTA is correctly filled, unless you contribute to the research community by the feedback.** Please see Appendix 2 how to feedback to the core facility.

APPENDIX 2: Instructions for feedback

Feedback of the observation is quite important for the research community for the future research plan. So, it is necessary to do so, even if you don't find any visible phenotype. If you can publish scientific papers, it is highly valuable. Please send reprints or equivalents to the core facility (TWMU) when you have published scientific papers upon distribution of the print version.

Followings are examples of phenotype description. Please try to describe what you have examined.

Ex1) "Fertile. Normal locomotion. Abnormal chemotaxis against diacetyl."

Ex2) "Abnormal dye-filling (Dyf) observed 33% of the animals."

Ex3) "Maternal effect larval lethal (L2-L3 stage). Homozygous adult worms from heterozygous hermaphrodites show abnormal chemotaxis against NaCl."

As can be seen in Appendix 1, feedback is necessary to receive more than 10 mutants.

Followings are "bad" examples and reasons:

Ex1) "Wild Type", reason: other researchers can not know what you examined.

Ex2) "No phenotype", reason: other researchers can not know what you examined.

Ex3) "lethal", reason: please describe at least the genetical trait and stage of death.